Scinai Immunotherapeutics Reports Remarkable Growth and Development in 2025 Financial Results Scinai Immunotherapeutics has showcased a significant leap in CDMO revenues and strategic collaborations in its latest financial results.

Scinai Immunotherapeutics Reports Remarkable Growth and Development in 2025 Financial Results #Israel #Jerusalem #Scinai #PC111 #Recipharm

Scinai Advances Promising Autoimmune Treatment with New Funding Application and Extended Agreement Scinai Immunotherapeutics has announced a revised application for non-dilutive funding to further develop its innovative PC111 treatment for severe autoimmune diseases.

Scinai Advances Promising Autoimmune Treatment with New Funding Application and Extended Agreement #Scinai_Immunotherapeutics #Israel #Jerusalem #PC111 #autoimmune_treatment

Scinai's PC111: A Promising New Therapy for Pemphigus and SJS/TEN Scinai Immunotherapeutics introduces PC111, a groundbreaking therapy shown to modify diseases like pemphigus and SJS/TEN, with promising safety and efficacy data.

Scinai's PC111: A Promising New Therapy for Pemphigus and SJS/TEN #Scinai_Immunotherapeutics #Israel #Jerusalem #PC111 #Pemphigus

Scinai Immunotherapeutics Celebrates Dr. Lotti's Award for PC111 Research in Italian Dermatology Scinai Immunotherapeutics proudly announces Dr. Roberta Lotti's recognition for groundbreaking research on PC111. This work marks a significant advancement in autoimmune treatment.

Scinai Immunotherapeutics Celebrates Dr. Lotti's Award for PC111 Research in Italian Dermatology #Scinai_Immunotherapeutics #Israel #Jerusalem #PC111 #Roberta_Lotti

Pioneering Treatment for Rare Skin Conditions: Scinai Webinar Highlights New Drug Development Scinai Immunotherapeutics is set to explore a groundbreaking drug for rare skin diseases in an upcoming webinar, focusing on PC111's significance.

Pioneering Treatment for Rare Skin Conditions: Scinai Webinar Highlights New Drug Development #Scinai_Immunotherapeutics #Israel #Jerusalem #Pincell #PC111

Scinai to Acquire Pincell and Advance Development of Groundbreaking Monoclonal Antibody Scinai confirms its acquisition of Pincell, focusing on a novel antibody for treating severe dermatological conditions and advancing its development with a significant grant application.

Scinai to Acquire Pincell and Advance Development of Groundbreaking Monoclonal Antibody #Israel #Jerusalem #Scinai #Pincell #PC111